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OBJECTIVE — To determine if baseline subgroups in the Action to Control Cardiovascular
Risk in Diabetes (ACCORD) trial can be identiﬁed for whom intensive compared with standard
glycemia treatment had different effects on all-cause mortality.
RESEARCH DESIGN AND METHODS — Exploratory post hoc intention-to-treat
comparisons were made between intensive and standard glycemia groups on all-cause mortality
by subgroups deﬁned by baseline characteristics.
RESULTS — There were few signiﬁcant interactions between baseline characteristics and
effects of intensive versus standard glycemia treatment on mortality: self-reported history of
neuropathy (hazard ratio [HR] 1.95, 95% CI 1.41–2.69) versus no history of neuropathy (0.99,
0.79–1.26; P value for interaction 0.0008), higher A1C (A1C 8.5%: HR 1.64, 95% CI 1.22–
2.22; A1C 7.5–8.4%: 1.00, 0.75–1.34; A1C 7.5%: 1.00, 0.67–1.50; P value for interaction
0.04), and aspirin use (HR 1.45, 95% CI 1.13–1.85, compared with 0.96, 0.72–1.27, in non-
users; P value for interaction 0.03).
CONCLUSIONS — We found a remarkable similarity of effect from intensive compared
with standard glycemia treatment on mortality across most baseline subgroups. No differential
effect was found in subgroups deﬁned by variables anticipated to have an interaction: age,
duration of diabetes, and previous history of cardiovascular disease. The three baseline charac-
teristics that deﬁned subgroups for which there was a differential effect on mortality may help
identify patients with type 2 diabetes at higher risk of mortality from intensive regimens for
glycemic control. Further research is warranted.
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N
umerous epidemiological studies
have demonstrated a relationship
betweenelevatedA1Candagreater
risk of cardiovascular (CVD) events and
mortalityintype2diabetes(1–3).There-
fore, it has been hypothesized that a re-
duction to near-normal levels of A1C in
patients with type 2 diabetes would re-
duce the risk of these adverse outcomes.
Three large randomized controlled clini-
cal trials testing this hypothesis in indi-
viduals with longstanding type 2 diabetes
reported their main results in the past 2
years (4–6).
The Data Safety Monitoring Board of
theActiontoControlCardiovascularRisk
in Diabetes (ACCORD) trial discontinued
the intensive glycemia arm because of an
increase in all-cause mortality in the in-
tensive glycemia arm compared with the
standardglycemiaarm.Theﬁndingofex-
cess mortality in the intensive arm of the
ACCORD trial has led to controversy
about implementation of intensive glu-
cose control in patients with type 2 dia-
betes (7,8). Adding to the controversy
were results of the Action in Diabetes and
VascularDisease:PreteraxandDiamicron
MR Controlled Evaluation (ADVANCE)
and Veterans Affairs Diabetes Trial
(VADT), demonstrating that although
there was no signiﬁcant reduction in the
primary end point of CVD events, there
was no increase in mortality with the in-
tensive glycemia arm compared with the
standard glycemia arm (4,6), which has
raised questions about reasons for these
discrepancies (9–12).
Acriticalquestionrelatestotheappli-
cabilityandgeneralizabilityoftheconclu-
sions of the ACCORD trial to the broader
populationortospeciﬁcsubgroupsofpa-
tients with type 2 diabetes. Indeed, pre-
speciﬁed subgroup analyses in ACCORD
did suggest a signiﬁcant beneﬁt of inten-
sive glycemic control on CVD events in
those participants with lower A1C at en-
try or absence of CVD event by history,
but there was no suggestion of a differen-
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observations are based on only a few sub-
group analyses at the time of the primary
publication. The effect on mortality of in-
tensive compared with standard glycemia
treatment may have been modiﬁed by
other possible characteristics of patients
at entry. We have therefore carried out
exploratory post hoc analyses of the ef-
fectsofintensivecomparedwithstandard
glycemia treatment in ACCORD partici-
pants categorized by various baseline
characteristics on all-cause mortality at
the time of discontinuation of the inten-
sive glycemia treatment of ACCORD,
with the goal to determine if particular
subgroupsathigherorlowerriskfromthe
intensive intervention can be identiﬁed.
RESEARCH DESIGN AND
METHODS— ACCORD is a multi-
center randomized clinical trial testing
the effect of very tight control of blood
glucose in patients with type 2 diabetes
compared with standard therapy on a
compositeoutcomeofCVDdeath,nonfa-
tal MI, and nonfatal stroke. The factorally
designed trial is also testing effects of in-
tensive blood pressure control compared
with standard (the Blood Pressure trial)
and use of fenoﬁbrate plus statin com-
pared with placebo plus statin (the Lipid
trial).
The treatment goal for the intensive
arm was an A1C of 6%, whereas the
treatment goal for the standard arm was
A1C of 7–7.9%, with the expectation that
themeanA1Cforthestandardarmwould
be 7.5%. The mean duration of the trial
was expected to be 5 years, but the inten-
sive glycemia arm of the study was dis-
continuedon5February2008becauseof
excess mortality in the intensive group,
and all participants were transitioned to
thestandardglycemiatreatmentprotocol.
Complete details of the study design and
conduct have been previously published
(13,14).
The dataset for the current analyses is
the same as that for the 2008 main results
paper, which includes all randomized
participantsfromenrollmentuntil10De-
cember 2007, an average trial follow-up
of 3.5 years (5). Subgroup deﬁnitions are
indicated in Table 1; baseline characteris-
tics to deﬁne the subgroups were divided
into four categories: 1) demographic and
anthropometric characteristics, 2) medi-
cal history characteristics, 3) medication
use, and 4) laboratory variables. Analyses
were conducted using intention-to-treat
comparisonsbetweentheintensiveglyce-
mia and standard groups on the mortality
rate within each subgroup as deﬁned in
Table 1 above (15). Analyses were con-
ductedattheACCORDcoordinatingcen-
ter using SAS 9.2 (SAS Institute, Cary,
NC). Cox proportional-hazards regres-
sionanalysiswasusedtoexaminetherisk
of all-cause mortality by glycemia arm
within each subgroup. A test of the inter-
action between the baseline variable and
treatment arm was done to assess homo-
geneity of the treatment effect across lev-
els of subgroups, i.e., to determine if
effects on mortality of intensive versus
standard glycemia treatments differed be-
tween the subgroup categories. All analy-
ses were adjusted for the study
stratiﬁcation factors: 1) history of CVD
(exceptfortheanalysisofCVDvariables),
2) assignment to the Lipid or Blood Pres-
sure trial (each trial had different eligibil-
ity criteria), 3) assignment to the Lipid
trial and randomized to fenoﬁbrate, and
4) assignment to the Blood Pressure trial
and randomized to the intensive blood
pressure intervention. Where possible,
categorical variables were also assessed as
continuous variables to determine if the
results differed from the categorical anal-
ysis. Multiple Cox regression analyses
were performed to determine if any ob-
served trends persist after adjusting for
multiple baseline characteristics. Because
these were exploratory analyses, no P
value adjustment was made for multiple
comparisons.
RESULTS— Overall, 257 participants
experienced the end point of all-cause
mortality in the intensive glycemia arm
and 203 participants experienced the end
point of all-cause mortality in the stan-
dard glycemia arm, as previously re-
ported (5.0 vs. 4.0%; hazard ratio (HR)
1.22; 95% CI 1.01–1.46; P  0.04) (10).
Tables of all the subgroup analyses
with all the variables examined are in the
online appendix (available at http://care.
diabetesjournals.org/cgi/content/full/dc09-
1471/DC1). Here we speciﬁcally note
those of signiﬁcance and borderline
signiﬁcance.
None of the baseline demographic
and anthropometric characteristics had a
statistically signiﬁcant interaction with
glycemia group assignment on mortality
(Fig. 1). The highest BMI category (35
kg/m
2) showed the highest HR for inten-
sive versus standard glycemia (HR 1.70,
95% CI 1.20–2.41) compared with BMI
30–34 kg/m
2 (1.05, 0.76–1.44) and
Table 1—Baseline variables
Demographics Medical history Medications Lab tests
Age, race/ethnicity, sex,
lives alone, clinical
network, BMI, waist
circumference,
education, year
randomization
Prior CVD event, prior coronary
heart failure, diabetes
duration, history of
neuropathy, peripheral
neuropathy, retinal
laser/surgery, visual acuity,
smoking, depression, blood
pressure, electrocardiogram
Sulfonylureas, metformin, thiazolidinediones,
any insulin HCTZ, ACE inhibitors,
-blockers, calcium-channel blockers,
ﬁbrates, statins, aspirin, antidepressants
A1C, LDL, HDL, triglyceride,
serum creatinine,
glomerular ﬁltration rate
(modiﬁed diet renal
disease), urinary albumin-
to-creatinine ratio
Demographics:age(65,65–69,70–74,75years),race/ethnicity(Hispanic,white,black,orother),livesalone(vs.withothers),clinicalcenternetwork(7CCNs),
BMI(30,30–34,35kg/m
2),waistcircumference(96.7,96.7–106.6,106.7–116,116.1cm),education(highschool,high-schoolgraduate,attendedsome
collegeortechnicalschool,collegegraduate),yearofrandomizationintoACCORD(2001–2005).Medicalhistory:diabetesduration(0–5,6–10,11–15,16years),
history of neuropathy/nerve problems (“Has the participant ever been told by a physician that he or she has neuropathy/nerve problems”: yes/no), peripheral
neuropathy (pedal amputation or a score 2 on the clinical examination portion of the MNSI), visual acuity (20/40, 20/20–20/40, 20/20), smoking status
(current, former, never), blood pressure (135, 135), electrocardiogram selected variables (any gross abnormalities, evidence of prior infarction, Q-T interval on
electrocardiogram corrected for heart rate QTc). Medication use: yes/no at baseline. Laboratory variables: A1C (7.5, 7.5–8.4, 8.5%), LDL cholesterol (100,
100–119, 120 mg/dl), HDL cholesterol (quartiles, mg/dl), triglycerides (300, 300 mg/dl), serum creatinine (0.1–1.0, 1 mg/dl), glomerular ﬁltration rate
(modiﬁed diet renal disease) (quartiles ml/min), urinary albumin-to-creatinine ratio (30, 30–300, 300 mg/g). HCTZ, hydrochlorotiazide.
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2(1.01,0.81–1.48;Pvalue
for interaction  0.078). Similarly, the
two highest quartiles for waist circumfer-
ence also showed the highest HR for in-
tensive versus standard glycemia (P value
for interaction  0.10). We did not ﬁnd
signiﬁcant interactions for age, sex, race,
living alone, clinical network, and educa-
tion level or randomization year.
Among the baseline medical history
subgroups (Fig. 1), participants with a
self-reported history of neuropathy/nerve
problemshadagreaterriskofmortalityin
the intensive glycemia arm compared
with the standard glycemia arm (P value
for interaction  0.0008). Moreover, the
interaction between self-reported history
of neuropathy/nerve problems and glyce-
mia arm continued to remain highly sig-
niﬁcant (P  0.006) after adjusting for
age, sex, waist circumference, smoking,
diabetes duration, hypoglycemic agents
used, history of retinopathy, history of
amputation, and systolic blood pressure.
However, the presence of peripheral neu-
ropathy at baseline, as documented by
pedal amputation or a score 2o nt h e
clinical examination portion of the Mich-
igan Neuropathy Screening Instrument
(MNSI)wasnotassociatedwithincreased
mortality in the intensive arm over the
standard arm (Fig. 1). We did not ﬁnd a
predictiveassociationforexcessmortality
in the intensive group for prior CVD dis-
ease, duration of diabetes, history of reti-
nalsurgery,smoking,depression,systolic
blood pressure, electrocardiogram vari-
ables, or prior amputation.
The analysis of medications reported
at baseline (Fig. 2) found that use of aspi-
rinwasassociatedwithexcessmortalityin
the intensive group (HR 1.45, 95% CI
1.13–1.85) compared with nonusers
(0.96, 0.72–1.27; P value for interac-
tion0.03).Asimilarbutnotstatistically
signiﬁcant differential effect occurred for
useofantidepressantmedicationsatbase-
line (HR 1.87, 95% CI 1.10–3.20, for us-
ers compared with 1.15, 0.94–1.40, for
nonusers;Pvalue for interaction0.08).
We did not ﬁnd any diabetes medication
or combination of diabetes medications
at baseline to be predictive of higher
mortality in the intensive group versus
the standard group. Furthermore, no hy-
polipidemic agent or antihypertensive
medicationhadaninteractionwithgroup
assignment in predicting mortality.
Laboratory test results at baseline
(Fig.2)foundthatparticipantswithbase-
line blood levels of A1C 8.5% in the
intensive glycemia arm had a higher risk
of death than the participants with the
same baseline levels in the standard arm
(HR 1.64, 95% CI 1.22–2.22), whereas
this increased risk was not apparent if
baseline A1C was 7.5% (1.00, 0.67–
1.50) or between 7.8 and 8.4% (1.00,
0.75–1.34) (P value for interaction 
0.04). None of the other lab values exam-
ined showed a statistically signiﬁcant in-
teraction with the glycemia trial arm,
Figure 1—Demographic characteristics and medical history. HRs are shown for all-cause mortality in intensive versus standard glycemia groups
within demographic and medical history subgroups, adjusted for the study stratiﬁcation factors: 1) history of CVD (except for the analysis of CVD
variables),2)assignmenttotheLipidorBloodPressuretrial(eachtrialhaddifferenteligibilitycriteria),3)assignmenttoLipidtrialandrandomized
to fenoﬁbrate, and 4) assignment to the Blood Pressure trial and randomized to the intensive blood pressure intervention.
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lycerides, serum creatinine, estimated
glomerular ﬁltration rate, or albumin-to-
creatinine ratio. Figure 3 shows the log of
the HR (compared with the standard arm
at baseline A1C of 7.0) for all-cause mor-
tality by treatment group. A visual review
indicates that after 8.2, the higher the
A1C at baseline in the intensive glycemia
group, the higher the participant’s risk.
No such relationship is seen in the stan-
dard glycemia group.
Multiple Cox regression analysis in-
cluding the three variables (self-reported
history of neuropathy, A1C, and aspirin
use) found to have statistically signiﬁcant
interactions with the glycemia arm at the
0.05 level lend support to the univariate
ﬁnding (A1C 8.5%, HR 1.64, 95% CI
1.22–2.22, P value for interaction 
0.0012), self-reported history of neurop-
athy/nerve problems at baseline (1.95,
1.41–2.7, P value for interaction
0.0001),anduseofaspirin(1.45,1.13–
1.85, P value for interaction  0.0032).
CONCLUSIONS— In these analyses
from ACCORD, we found a remarkable
similarity of effect on mortality of inten-
sive compared with standard glycemia
arm assignment across numerous post
hoc baseline subgroups. Importantly, no
differential effect of intensive versus stan-
dard treatment on mortality was found in
subgroups deﬁned by variables antici-
pated to have such an interaction: age,
duration of diabetes, previous history of
CVDdisease(Figs.1–2).Nevertheless,we
didﬁndthattheintensivetreatmenthada
higher effect on mortality in subgroups
deﬁned by three baseline clinical vari-
ables: A1C 8.5% (interaction P 
0.044),aspirinuse(interactionP0.03),
and self-reported history of neuropathy/
nerveproblems(interactionP0.0008).
However, because of the multiple com-
parisons and the post hoc nature of these
analyses, the interaction P values for A1C
andaspirinuseshouldonlybeconsidered
suggestive. A marginal differential effect
also was found in subgroups with higher
BMI and higher waist circumference at
baseline.
Consistent with the prevailing epide-
miologic evidence of the relationship be-
tween glycemic control and mortality (1–
3,16,17), the increase in mortality in the
intensive arm was observed among those
participants with higher (8.5%) com-
pared with lower (8.5%) A1C at base-
line. This effect was evident when A1C
wasexaminedasacategoricalvariablebut
was seen to a lesser extent when we ex-
aminedA1Casacontinuousvariable.The
splineplotofHRsacrosslevelsofbaseline
A1C imply an increasingly higher risk
with higher baseline A1C in the intensive
arm,butnotinthestandardarm.Individ-
ualswithhigherA1Catbaselinemayrep-
Figure 2—Medication and laboratory tests. HRs are shown for all-cause mortality in intensive versus standard glycemia groups within the
medicationandlaboratorytestssubgroupsadjustedforthestudystratiﬁcationfactors:1)historyofCVD(exceptfortheanalysisofCVDvariables),
2) assignment to the Lipid or Blood Pressure trial (each trial had different eligibility criteria), 3) assignment to Lipid trial and randomized to
fenoﬁbrate, and 4) assignment to the Blood Pressure trial and randomized to the intensive blood pressure intervention.
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diseasetomanageand/orindividualswho
may adhere less to therapy. Whether in-
dividuals at highest risk ultimately
achieved or failed to achieve more inten-
sive treatment targets will require addi-
tional analysis.
Baselineparticipantreportofneurop-
athy/nerve problems deﬁned a subgroup
in which the intensive approach for gly-
cemia treatment had a differential effect
on mortality, with a highly signiﬁcant P
value of 0.0008. Peripheral neuropathy is
a common complication of diabetes, and
excess mortality has been related to di-
minished peripheral sensation (16,18),
foot ulceration, and history of lower-
extremity amputation (19). Yet in our co-
hort, neither MNSI-documented
peripheral neuropathy nor history of am-
putationwasassociatedwithadifferential
effect on mortality from intensive com-
pared with standard glycemia treatment
(although very few participants with an
amputation entered the study). The dis-
crepancy suggests the two methods of de-
tecting neuropathy may identify different
populations. Indeed, the MNSI detected
peripheral neuropathy in 4,357 partici-
pants in contrast to 2,737 participants
who reported a history of neuropathy, of
whom61%hadalsoanMNSIscoreindic-
ative of neuropathy. The discordance
among various indexes of neuropathy in
their strength for predicting outcomes
(symptoms versus physical ﬁndings) was
also apparent in the DIAD study (20),
where a signiﬁcant relation to CVD out-
comes was found with one symptom
(numbness) and one sign (“absent sensa-
tion”),butitwasborderlineforadifferent
symptom(pain)andhadnorelationtoyet
another symptom (tingling) and two
physical signs (absent vibration, absent
reﬂex). The discrepancy does not dimin-
ish the possible importance of neuropa-
thy as a predictor for worse outcomes
from intensive glycemia treatment, or
even as an etiologic agent of CVD out-
comes or mortality; this issue deserves
further study.
Lastly, there was a differential effect
on mortality of intensive compared with
standard treatment by use of aspirin at
baseline. Although aspirin use is recom-
mended for patients with type 2 diabetes
(21),theevidencesupportingitsbeneﬁtis
nowbeingreconsidered(22).Recentclin-
ical trials including or limited to those
with type 2 diabetes (23–25) have not
shown a signiﬁcant reduction in either
CVD mortality or overall mortality in pa-
tientswithtype2diabetes,althoughthese
studies often included populations con-
sidered to be at lower risk of CVD disease
than the population recruited for the
ACCORD trial. A possible explanation
couldbethataspirinuseismerelyaproxy
for those at higher risk of CVD disease,
Figure3—A1Candall-causemortality.SplinecurvesdisplayingthelogoftheHRforall-causemortalitybytreatmentandbaselineA1Careshown.
All HRs are with respect to standard glycemia with baseline A1C of 7.0. The bold line represents the intensive treatment group, the ﬁner line the
standard group, and the colored lines the 95% CIs.
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among those with a history of CVD dis-
ease at baseline.
There are a number of important
limitations to the analyses conducted
for this article. First, we cannot exclude
the possibility that the ﬁndings of sig-
niﬁcant interactions are due to chance
alone. For a set of 38 independent vari-
ables, we would expect to ﬁnd P  0.05
for at least 1.9 variables by chance
alone, suggesting the results for A1C
and aspirin use should be interpreted
with caution, since P values were very
close to the 0.05 level. Nonetheless,
self-report of neuropathy had a very
strong statistical signiﬁcance. Data from
other sources will be required for con-
ﬁrmation of the ﬁndings presented.
Many of the baseline characteristics
were self-reported by participants; al-
though a certain amount of misclassiﬁ-
cation may be expected, we would not
expect this to differ by study arm. Fi-
nally, these analyses should be consid-
ered exploratory and hypothesis
generating, since the subgroups were
not deﬁned a priori and ACCORD was
not powered to look at speciﬁc sub-
groups—nor was the study powered for
an analysis of mortality, since the pre-
speciﬁed primary outcome was the rate
of major CVD events.
In summary, we have identiﬁed three
baseline characteristics that deﬁned sub-
groups in which there was a differential
effect on mortality of the intensive com-
pared with standard glycemia treatment
in ACCORD: A1C 8.5%, self-reported
history of neuropathy, and aspirin use at
study entry. The interactions in the A1C
and aspirin use were of marginal signiﬁ-
cance and can only be considered sugges-
tive and will require additional study. Of
note is that the most signiﬁcant associa-
tionfoundwaswithself-reportofneurop-
athy. Importantly, other baseline char-
acteristicsthatwerehypothesizedtoiden-
tify subgroups with differential effects on
mortality by treatment arm did not have
such interaction, including increasing
age, duration of diabetes, and history of
CVD disease. Further analysis of the role
of neuropathy on mortality in type 2 dia-
betes is warranted. The ACCORD study
group is currently performing additional
analyses to deﬁne the possible role of au-
tonomic neuropathy—as well as other
factors—in the outcomes observed.
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